Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
about
VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer CellsEFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.The emerging quest for the optimal angiostatic combination therapy.Targeting metastasis.Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cellsTranslational aspects in targeting the stromal tumour microenvironment: from bench to bedside.LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.Direct effect of bevacizumab on glioblastoma cell lines in vitro.Tumor cell response to bevacizumab single agent therapy in vitroA truncated-Flt1 isoform of breast cancer cells is upregulated by Notch and downregulated by retinoic acid.Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.The potential role of nintedanib in treating colorectal cancer.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities.Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes.Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of ComplemicroRNA-451a regulates colorectal cancer proliferation in response to radiation.
P2860
Q28607569-3A1BCF78-0C98-4D96-9690-83BF18EECC2DQ30490563-4F69D2EA-4487-46D0-AC8E-4E1472A99FBFQ33356339-665176D5-E7E8-4710-8557-6828A18BCD6DQ33688593-A891B1B9-41C8-4B9B-94D8-3BCC6049648EQ33700204-E7ADA97C-4281-483D-AB60-D574F5C9E84DQ33770680-F03FCE74-4670-4DB0-B898-E1706E541313Q34103998-9FC72761-5BE7-45AA-A9A2-B795CCEE1BDEQ34708917-3C50C493-3FB8-4262-99D3-DFB4FFA167C3Q35412202-CCD01F8F-C3B9-4246-A904-2344D0146215Q35923178-03E0C8BD-F0AE-47AA-A025-9ACF394E5430Q36545367-0227C484-9216-4258-8180-44545635E730Q36918194-BB1B7C9F-7591-4B3C-9F8E-104E1EA8A381Q37059490-EBF1B183-592E-4B94-916D-98C140F4C114Q37687310-B5E70CB0-BECC-49B8-8100-A39FAE3351C4Q38027969-68267DBD-303C-43FE-8E3B-8C394BCE984AQ38268453-2355F29A-6DD6-4CC8-845C-CDA870E9AD87Q38786658-900B4479-693E-4172-98FE-943298CD2718Q38821600-792BBD53-1490-464B-9823-11C5C9A521E4Q38858806-522492ED-2C0B-4A25-A2E9-A0C9D3FBBAAAQ38913406-1E1EBF4C-0BD0-4216-8F50-CCB60DE79C2BQ38942748-CE919469-39A3-4C71-BF2C-DECDFBA23E72Q38967004-5EE71190-92F8-4DAF-870E-2BB5F27851DDQ39092845-AE646F16-D1C1-47C3-8647-50A01357FAE6Q39117307-622F4AD4-59D5-4FBF-95A1-AA09931488D7Q39206159-B2624A7F-9064-4937-A00E-3C1EC0B7FB5DQ39398037-FF4F28BF-4B74-4181-A7EF-AFFB49F2D1BAQ39403862-6D7ECAEC-C3C7-4CD4-B7E9-7A5F1BA34B3AQ41892249-B05DE0F4-92EC-421F-BCD5-5E67ED50C713Q42402968-0B4EB9AA-DB2D-4D84-A261-A0F77FA20BFFQ44456046-DE902DE7-375A-40CE-9F1D-DCCFEB6C91BBQ46126845-402FA69A-2037-4B5C-AF21-FB73E0BFF0C0Q49833366-0509B163-ABE8-47FA-B7B2-481710E47FD6Q53779084-C3D3D72A-9861-4F1B-A9F6-E578FD47E8C4Q55154231-B57C3557-22B9-4365-921E-940156CFCA4E
P2860
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chronic exposure of colorectal ...... mediate tumour cell migration.
@ast
Chronic exposure of colorectal ...... mediate tumour cell migration.
@en
Chronic exposure of colorectal ...... mediate tumour cell migration.
@nl
type
label
Chronic exposure of colorectal ...... mediate tumour cell migration.
@ast
Chronic exposure of colorectal ...... mediate tumour cell migration.
@en
Chronic exposure of colorectal ...... mediate tumour cell migration.
@nl
prefLabel
Chronic exposure of colorectal ...... mediate tumour cell migration.
@ast
Chronic exposure of colorectal ...... mediate tumour cell migration.
@en
Chronic exposure of colorectal ...... mediate tumour cell migration.
@nl
P2093
P2860
P356
P1476
Chronic exposure of colorectal ...... mediate tumour cell migration.
@en
P2093
N A Dallas
V Ramachandran
P2860
P2888
P304
P356
10.1038/BJC.2011.81
P407
P577
2011-03-15T00:00:00Z
P5875
P6179
1005084446